UroGen Pharma Ltd. (NASDAQ:URGN) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets decreased its position in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 43.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,801 shares of the company’s stock after selling 3,745 shares during the quarter. BNP Paribas Financial Markets’ holdings in UroGen Pharma were worth $51,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of the company. Ameriprise Financial Inc. boosted its holdings in shares of UroGen Pharma by 9.3% during the fourth quarter. Ameriprise Financial Inc. now owns 49,153 shares of the company’s stock valued at $523,000 after acquiring an additional 4,188 shares during the period. Acorn Capital Advisors LLC bought a new stake in shares of UroGen Pharma during the fourth quarter valued at about $16,149,000. Nantahala Capital Management LLC bought a new stake in shares of UroGen Pharma during the fourth quarter valued at about $14,608,000. Northern Trust Corp raised its stake in shares of UroGen Pharma by 8.1% during the fourth quarter. Northern Trust Corp now owns 310,074 shares of the company’s stock valued at $3,302,000 after purchasing an additional 23,345 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its stake in shares of UroGen Pharma by 178.1% during the fourth quarter. The Manufacturers Life Insurance Company now owns 37,486 shares of the company’s stock valued at $399,000 after purchasing an additional 24,006 shares in the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

UroGen Pharma Price Performance

NASDAQ URGN opened at $5.00 on Wednesday. The stock’s 50-day moving average price is $8.99 and its two-hundred day moving average price is $10.28. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The company has a market cap of $230.54 million, a PE ratio of -1.59 and a beta of 0.66. UroGen Pharma Ltd. has a 1 year low of $3.42 and a 1 year high of $20.70.

UroGen Pharma (NASDAQ:URGN) last posted its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The business had revenue of $20.25 million during the quarter, compared to analysts’ expectations of $22.71 million. On average, analysts predict that UroGen Pharma Ltd. will post -3.12 EPS for the current year.

Analyst Upgrades and Downgrades

URGN has been the topic of a number of recent analyst reports. Oppenheimer cut their price objective on shares of UroGen Pharma from $36.00 to $10.00 and set an “outperform” rating on the stock in a research note on Tuesday. HC Wainwright cut shares of UroGen Pharma from a “buy” rating to a “neutral” rating in a research note on Thursday, May 22nd. Guggenheim cut their price objective on shares of UroGen Pharma from $40.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, May 23rd. Scotiabank initiated coverage on shares of UroGen Pharma in a research note on Wednesday, April 16th. They set a “sector outperform” rating and a $23.00 price objective on the stock. Finally, LADENBURG THALM/SH SH initiated coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They set a “buy” rating and a $31.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.14.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.